未找到相关数据
A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.
被引：4
作者：
Shapiro, J. D.
Siu, L. L.
Zalcberg, J. R.
Moore, M. J.
Ringash, J.
Mittmann, N.
Simes, J.
O'Callaghan, C. J.
Tu, D.
Walters, I. B.
Magoski, N.
Smith, P.
Nomikos, D.
Zhu, L.
Savoie, M.
Virk, S.
El-Tahche, F.
Gill, R.
Price, T. J.
Jonker, D. J.
机构：
[1] Cabrini Hosp, Malvern, Australia
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[7] ANZGOG, Camperdown, NSW, Australia
[8] NCIC Clin Trials Grp, Kingston, ON, Canada
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[10] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[11] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[12] Ottawa Hosp, Ottawa, ON, Canada
[13] Univ Ottawa, Ottawa, ON, Canada
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS163
引用
收藏
页数：1
相关论文